Recent Investment Analysts’ Ratings Updates for Verastem (VSTM)

Verastem (NASDAQ: VSTM) has recently received a number of price target changes and ratings updates:

• 3/12/2026 – Verastem is now covered by BTIG Research. They set a “buy” rating and a $19.00 price target on the stock.
• 3/11/2026 – Verastem was upgraded by BTIG Research to “strong-buy”.
• 3/7/2026 – Verastem was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/5/2026 – Verastem had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $19.00 price target on the stock.
• 2/19/2026 – Verastem was given a new $18.00 price target by Mizuho.
• 2/4/2026 – Verastem is now covered by HC Wainwright. They set a “buy” rating and a $18.00 price target on the stock.

Insider Buying and Selling at Verastem

In related news, CFO Daniel Calkins sold 5,039 shares of the company’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $7.16, for a total transaction of $36,079.24. Following the completion of the sale, the chief financial officer directly owned 104,719 shares in the company, valued at $749,788.04. This represents a 4.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Dan Paterson sold 10,321 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $7.16, for a total value of $73,898.36. Following the sale, the chief executive officer directly owned 400,104 shares in the company, valued at approximately $2,864,744.64. The trade was a 2.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 16,330 shares of company stock worth $116,467 in the last ninety days. Insiders own 2.10% of the company’s stock.

Verastem Oncology, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S.